Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Apogee Therapeutics

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

The $11 Billion Reason Abbvie Stock Is Up Today

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

US stocks drift after oil prices ease and Big Tech stocks fall

U.S. stocks drifted through a mixed day of trading after oil prices eased and falling Big Tech stocks weighed on Wall Street

US stocks end mixed, weighed down by drops in Big Tech, even as oil prices fall

U.S. stocks drifted through a mixed day of trading after oil prices eased and falling Big Tech stocks weighed on Wall Street

US stocks drift near their records in mixed trading after oil prices fall

U.S. stocks are drifting near their records in mixed trading

US stocks drift near their records after oil prices fall

U.S. stocks are drifting near their records after trading resumed following a three-day weekend

inkl

Read news from The Economist, FT, and more,
with one subscription

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

Top 2 Health Care Stocks That May Plunge This Month

Top 2 Health Care Stocks That May Plunge This Month

As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.

2 Russell 2000 Stocks With More Than 29% Upside Potential to Grab Now

2 Russell 2000 Stocks With More Than 29% Upside Potential to Grab Now

Wall Street rates both of these outperforming small-cap stocks a “strong buy," with 29% or more upside expected over the next year.

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap peers so far this year.

1

People

Michael Henderson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Viking Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

417,537 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play